glp 1 receptor agonist moa GLP-1 Agonists as Treatments for Type 2 Diabetes The dual glucose-dependent insulinotropic polypeptide

Data from Qk041 batch #104315

Available at: (Accessed November 14, 2022)

A MOF occurred in 1.8% (n = 286) and 1.7% (n = 274) of GLP-1 RA users and DPP-4i users, respectively

While they produce modest LDL cholesterol reductions of 2-10%, statins remain first-line therapy for patients requiring significant lipid lowering, and GLP-1 agents work best as complementary therapy alongside statins

It says plans use the label to manage formulary costs, ensure appropriate patient selection, and monitor for adverse events, reflecting the need for ongoing provider communication and potential adjustment over time

Neurosci Lett 52:S18 Li X, Zhang C, Zhang X et al (2015) An acetyl-l-carnitine switch on mitochondrial dysfunction and rescue in the metabolomics study on aluminium oxide nanoparticles